Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma
NCT04851132Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival at 1 year. Status: unknown.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04851132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851132.